Novel agents for myeloma
Actions . | Agents . |
|---|---|
| Targeting both MM cells and interaction of MM cells with the bone marrow microenvironment | Thalidomide and its analogs (Revlimid) |
| Proteasome inhibitor (bortezomib) | |
| Arsenic trioxide | |
| 2-Methoxyestradiol (2-ME2) | |
| Lysophosphatidic acid acyltransferase-β inhibitor | |
| Triterpenoid 2-cyano-3, 12-dioxoolean-1, 9-dien-28-oic acid (CDDO) | |
| N-N-diethl-8,8-dipropyl-2-azaspiro [4.5] decane-2-propanamine (Atiprimod) | |
| Targeting circuits mediating MM cell growth and survival | VEGF receptor tyrosine kinase inhibitor (PTK787/ZK222584, GW654652) |
| Farnesyltransferase inhibitor | |
| Histone deacetylase inhibitor (SAHA, LAQ824) | |
| Heat shock protein-90 inhibitor (Geldanamycin, 17-AAG) | |
| Telomerase inhibitor (Telomestatin) | |
| bcl-2 antisense oligonucleotide (Genasense) | |
| Inosine monophosphate dehydrogenase (VX-944) | |
| Rapamycin | |
| Targeting the bone marrow microenvironment | IκB kinase (IKK) inhibitor (PS-1145) |
| p38 MAPK inhibitor (VX-745, SCIO-469) | |
| TFG-β receptor inhibitor (SD-208) | |
| Targeting cell surface receptors | TNF-related apoptosis-inducing ligand (TRAIL)/Apo2 ligand |
| IGF-1 receptor inhibitor (ADW) | |
| HMG-CoA reductase inhibitor (Statins) | |
| Anti-CD20 antibody (Rituximab) |
Actions . | Agents . |
|---|---|
| Targeting both MM cells and interaction of MM cells with the bone marrow microenvironment | Thalidomide and its analogs (Revlimid) |
| Proteasome inhibitor (bortezomib) | |
| Arsenic trioxide | |
| 2-Methoxyestradiol (2-ME2) | |
| Lysophosphatidic acid acyltransferase-β inhibitor | |
| Triterpenoid 2-cyano-3, 12-dioxoolean-1, 9-dien-28-oic acid (CDDO) | |
| N-N-diethl-8,8-dipropyl-2-azaspiro [4.5] decane-2-propanamine (Atiprimod) | |
| Targeting circuits mediating MM cell growth and survival | VEGF receptor tyrosine kinase inhibitor (PTK787/ZK222584, GW654652) |
| Farnesyltransferase inhibitor | |
| Histone deacetylase inhibitor (SAHA, LAQ824) | |
| Heat shock protein-90 inhibitor (Geldanamycin, 17-AAG) | |
| Telomerase inhibitor (Telomestatin) | |
| bcl-2 antisense oligonucleotide (Genasense) | |
| Inosine monophosphate dehydrogenase (VX-944) | |
| Rapamycin | |
| Targeting the bone marrow microenvironment | IκB kinase (IKK) inhibitor (PS-1145) |
| p38 MAPK inhibitor (VX-745, SCIO-469) | |
| TFG-β receptor inhibitor (SD-208) | |
| Targeting cell surface receptors | TNF-related apoptosis-inducing ligand (TRAIL)/Apo2 ligand |
| IGF-1 receptor inhibitor (ADW) | |
| HMG-CoA reductase inhibitor (Statins) | |
| Anti-CD20 antibody (Rituximab) |